- 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 - - Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared to baseline at 12 months after two 16 mg doses of CYB003 - - Findings validate dosing regimen and confirm that CYB003's effects are highly durable and offer sustained relief for MDD patients - - CYB003 continues to be well-tolerated and demonstrates an excellent safety profile - - Cybin's Phase 3 PARADIGM TM multinational pivotal program evaluating the efficacy and safety of CYB003 has been initiated - - Company to

- Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 - - Presentation will also include discussion of its recently initiated Phase 3 PARADIGM program for CYB003 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at 8:00 a.m. ET. The event will be hosted by Cybin's Chief Executive Officer, Doug Drysdale, and Cybin's Chief Medical Officer, Amir Inamdar, and will incl

- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - APPROACH ™: A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans with Major Depressive Disorder has been initiated and will enroll 220 patients at 36 clinical sites across the U.S. and Europe; topline results expected in 2026 - - EMBRACE ™: An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active and 1 Inactive Oral Doses of CYB003 in Eligible Participants with Major Depressive Disorder is expected to beg

- CEO Doug Drysdale to speak on panel about novel approaches to mental health treatments on November 13, 2024 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Doug Drysdale, Cybin's Chief Executive Officer, will be speaking at the 2024 Milken Institute Future of Health Summit on a panel entitled "The Next Frontier in Mental Health Research." "We share the Milken Institute's inspiring commitment to accelerating medical research and improving health outcomes and are pleased to

Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in the Water Tower Research Fireside Chat Series taking place on Tuesday, October 8, 2024, at 3:00 p.m. ET. The fireside chat will be hosted by Robert Sassoon, Senior Research Analyst at Water Tower Research. Covered topics will include: Cybin's lead development programs CYB003 and CYB004 and upcoming clinical milestones. What differentiates Cybin's development ap

- Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder ("MDD") imminently - - Cybin welcomes Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo Gutierrez as Vice President, Clinical Pharmacology - - Other recent additions to the team include project directors. project managers, and clinical monitoring managers, as well as previously announced senior leadership team hires, and program lead for CYB003 - - Strengthened team in place to support CYB003 pivotal trials, which will consist of three studies spanning up to 12 countries - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company")

ST. PETERSBURG, FL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Cybin, Inc. (NYSE AM: CYBN) titled, "A Leader in Novel Neuropsychiatry Therapeutics". The report can be accessed here. A leader in novel neuropsychiatric therapeutics. Stewarded by a highly experienced and accomplished executive management team with deep and broad pharma industry knowledge, Cybin has been positioned as the most advanced developer of innovative neuropsychiatry treatments targeting hard-to-treat mental health disorders that affect large swathes of the global population, including major depressive disorder (MDD) and gene

Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Amir Inamdar, Cybin's Chief Medical Officer, will participate in a panel discussion at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit taking place virtually on September 26, 2024. The panel discussion, titled "Advancement in Psychedelic Therapies for Neuropsychiatry," will be webcast live on Thursday, September 26, 2024, at 10:00 a.m. ET. To listen to the event, please click here to access the webcast. The archi

- Initiation of pivotal CYB003 Phase 3 study in Major Depressive Disorder ("MDD") expected imminently - - 12-month efficacy data from Phase 2 study of CYB003 in MDD expected in early Q4 2024 - - Phase 2 topline efficacy and safety results for CYB004 in Generalized Anxiety Disorder ("GAD") expected year-end 2024 or early Q1 2025 - - Strengthened R&D team with addition of experienced drug development leaders Dr. Atul R. Mahableshwarkar, and Dr. Tom Macek, as program leads for CYB003 and CYB004, respectively - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing n

Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that it has filed articles of amendment to consolidate the Company's issued and outstanding common shares (the "Common Shares") on the basis of one new Common Share for every 38 existing Common Shares (the "Consolidation"). The Consolidation is effective immediately and trading of the Common Shares reflecting the Consolidation will commence at the opening of trading today. As a result of the Consolidation, the 759,692,495 Common Shares

SC 13G/A - CYBIN INC. (0001833141) (Subject)

SC 13G/A - CYBIN INC. (0001833141) (Subject)

SC 13G - CYBIN INC. (0001833141) (Subject)

SC 13G - CYBIN INC. (0001833141) (Subject)

SC 13G - CYBIN INC. (0001833141) (Subject)

SC 13G/A - CYBIN INC. (0001833141) (Subject)

SC 13G/A - CYBIN INC. (0001833141) (Subject)

SC 13G - CYBIN INC. (0001833141) (Subject)

SC 13G - CYBIN INC. (0001833141) (Subject)

SC 13G/A - CYBIN INC. (0001833141) (Subject)

- Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder ("MDD") imminently - - Cybin welcomes Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo Gutierrez as Vice President, Clinical Pharmacology - - Other recent additions to the team include project directors. project managers, and clinical monitoring managers, as well as previously announced senior leadership team hires, and program lead for CYB003 - - Strengthened team in place to support CYB003 pivotal trials, which will consist of three studies spanning up to 12 countries - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company")

Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) (Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on August 27, 2024 (the "Meeting"). There were 87 shareholders represented in person or by proxy at the Meeting holding 453,195,063 common shares, representing 59.66% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are

- Dr. Mahableshwarkar, a Board-Certified Psychiatrist, is an experienced pharmaceutical industry leader with decades of expertise in drug development - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, has joined the Company as Senior Vice President, Clinical Development. Dr. Mahableshwarkar will lead the development of the CYB003 program, Cybin's proprietary deuterated psilocybin analog which has received U.S. Food and Drug Admini

Cybin Inc. (NYSE:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on October 12, 2023 (the "Meeting"). There were 66 shareholders represented in person or by proxy at the Meeting holding 91,903,025 common shares, representing 39.16% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out belo

This news release constitutes a "designated news release" for the purposes of Cybin's prospectus supplement dated August 8, 2022 and prospectus supplement dated May 30, 2023 to its short form base shelf prospectus dated July 5, 2021 Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce the appointment of Aaron Bartlone as Chief Operating Officer of Cybin Inc., effective July 1, 2023. Mr. Bartlone has served as Chief Operating Officer of Cybin's U.S. subsidiary, Cybin US Holdings, Inc., since March 202

Cybin Inc. (NYSE:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Mr. Sanford R. Climan has joined Cybin as a strategic advisor. Mr. Climan is the CEO and founder of Entertainment Media Ventures, Inc., a Los Angeles based advisory and investment company specializing in identifying opportunities in healthcare, technology, and media & entertainment industries. Widely viewed as a media visionary, Mr. Climan is an active venture investor, board member, and senior advisor to a wide range of transformational compa

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 15, 2022 (the "Meeting"). There were 71 shareholders represented in person or by proxy at the Meeting holding 47,019,721 common shares, representing 28.3% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting is set out below: 1. Appointment of Auditor Zeifmans LLP was appointed auditor of Cybin until the next

FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of "magic" mushrooms can be used to treat depression. Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. According to CAMH's lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce "sustained antidepressant effects" in individuals living with severe depression. This news comes just days after a major scientific review found "no clear evidence

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to provide a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the Company for a transformative 2022. "2021 was an exciting year for Cybin. We expanded our organization from 5 to more than 55 employees across 4 countries and have established an operating ecosystem of nearly 50 partners and vendors that have supported more than 90 preclinical studies and numerous patent and investigational new drug filings over the past 12 months," said Doug Drysdale, Cybin's Chief Executive Officer. "D

The Company Also Welcomes Leah Gibson as its New Vice President of Investor Relations Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today announced that the Company has been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency ("DEA"). The DEA license is a federal requirement for any investigators who intend to study, produce, analyze or otherwise work with Schedule I controlled substances. The DEA license is for the Company's research lab in the Boston area. The license will allow the Company to further become a hub for innovation and drug discovery. Previously

https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted that MDMA therapies have been proven safe and effective by multiple studies.As an August deadline for the U.S. Food and Drug Administration looms regarding approval for psychedelic therapies, a coalition of well-known scientific researchers took it upon itself to publicize its support for midomafetamine (MDMA)-based treatment for patients with post-traumatic stress disorder.In an online consensus statement, 23 medical doctors and researchers urged the FDA to accept MDMA therapy for PTSD, noting that more than 17 U.S. military veterans commit suicide each day due to

Cybin Inc. (AMEX:CYBN) (CBOE: CYBN), a clinical-stage biopharmaceutical company focused on developing next-generation psychedelic treatments for mental health disorders, announced Wednesday its financial results for the fiscal quarter and year ending March 31, 2024, alongside significant strides in psychedelic therapy development.  Cybin reported a net loss of C$78 million ($57 million) for FY 2024, a noticeable increase from C$47 million the previous year. Fiscal Year 2024 Financial Highlights No profits or revenues reported. Net loss was C$78 million. Cash totaled C$209 million as of March 31, 2024. Closed oversubscribed private placement of $150 million led by a syndicate

Cantor Fitzgerald analyst Charles Duncan reiterates Cybin (AMEX:CYBN) with a Overweight.

As the premier gathering of top entrepreneurs and investors took place on Monday in New Jersey, we thought it would be a good time to scroll through the latest leadership changes in the cannabis and psychedelics industries. Cybin Inc. (NYSE:CYBN) (Cboe CA: CYBN) a clinical-stage biopharmaceutical company that develops new and innovative next-generation psychedelic-based treatment options, announced recently that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, opted to join the company as senior vice president of clinical development. Dr. Mahableshwarkar agreed to lead the development of the CYB003 program, Cybin's proprietary deuterated psilocybin analog which has received U.S. Food and Drug

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after-launching/"Unfortunately we've seen one service center close down. I imagine there will be more, because very quickly it's going to get oversaturated."By Grant Stringer, Oregon Capital ChronicleA year in, Oregon's experiment with the first regulated psilocybin mushroom market in the world is short on customers.To attract them, advocates say the industry needs to get the word out about its benefits."We think everybody knows that psychedelics can help them because we're in this little bubble. But 99 percent of people have no idea what they could get out of a journey,"

A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.Some members of the panel, like sociologist Elizabeth Joniak-Grant, pointed to allegations of misconduct in trials th

HC Wainwright & Co. analyst Patrick Trucchio reiterates Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.

Florida-based cannabis company Kaya Holdings Inc ., AKA KAYS, (OTCQB:KAYS) has been awarded a license by the Oregon Health Authority to operate a Psilocybin Service Center. Oregon is the only state in the US that has developed a licensing framework that allows for the administration of psilocybin in a safe and legal setting under the guidance of State Licensed Facilitators. KAYS through its Fifth Dimension Therapeutics, Inc. subsidiary, plans to operate The Sacred Mushroom, a full-service psychedelic treatment center that will allow clients to receive psilocybin treatment in a setting offering significant experience differentiators and concept innovations. The Sacred Mushroom expects to s

- 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 - - Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared to baseline at 12 months after two 16 mg doses of CYB003 - - Findings validate dosing regimen and confirm that CYB003's effects are highly durable and offer sustained relief for MDD patients - - CYB003 continues to be well-tolerated and demonstrates an excellent safety profile - - Cybin's Phase 3 PARADIGM TM multinational pivotal program evaluating the efficacy and safety of CYB003 has been initiated - - Company to

- Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 - - Presentation will also include discussion of its recently initiated Phase 3 PARADIGM program for CYB003 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at 8:00 a.m. ET. The event will be hosted by Cybin's Chief Executive Officer, Doug Drysdale, and Cybin's Chief Medical Officer, Amir Inamdar, and will incl

- Breakthrough Therapy Designation ("BTD") provides an expedited review pathway, as well as increased access to U.S. Food and Drug Administration ("FDA") guidance on trial design, with the potential to significantly reduce drug development timelines - - First known BTD granted by the FDA for an adjunctive psychedelic based therapy for the treatment of Major Depressive Disorder ("MDD") - - Robust, sustained and statistically significant improvement in depression symptoms at four months with 75% of patients in remission from depression after two doses (16mg) - - Impressive mean 22-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score from baseline at four months -

 - Program update includes 4-month durability data from Phase 2 trial of CYB003 in Major Depressive Disorder ("MDD") - - Company speakers include Doug Drysdale, Chief Executive Officer and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that it will host a conference call and webcast at 8:30 a.m. ET on Wednesday, March 13, 2024. The Company will provide a program update on CYB003, its proprietary deuterated psilocybi

- Announced unprecedented positive Phase 2 interim data for CYB003, its proprietary deuterated psilocybin analog, in major depressive disorder - - Announced closing of a unit offering of up to US$64 (C$88.4) million led by one of its largest institutional shareholders - - Strengthened patent portfolio with the addition of four new patents - - Completed acquisition of Small Pharma Inc. - - Topline clinical readout of Phase 2 efficacy data for CYB003 expected in Q4 20231 - - Topline clinical readout of Phase 1 data for CYB004 and SPL028 expected around year end 20231 - Cybin Inc. (NYSE:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committe

- Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET - - Complete Phase 2 topline data for CYB003 in MDD expected in Q4 2023 - Cybin Inc. (NYSE:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today provided an update on its clinical-stage programs and key upcoming milestones across its development pipeline. "The clinical progress we have made over the past few months is truly remarkable, exemplified by our recently released positive Phase 2 in

- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) - - For reference, pooled data from 232 industry studies of current standard of care antidepressants, selective serotonin reuptake inhibitors (SSRIs), submitted to U.S. Food and Drug Administration ("FDA") (Stone et al, 2022) show an average improvement of 1.82 points vs. placebo - - Robust response and remission three weeks after single dose, with 53.3% of patients responding and 20% of pa

Cybin Inc. (NYSE:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its 2023 Annual and Special Meeting of Shareholders will be held virtually on Thursday, October 12, 2023 at 1:00 p.m. ET. The notice of annual and special meeting and proxy statement containing meeting details are available under the Company's profile on SEDAR+ at www.sedarplus.ca, and on the Company's website at www.cybin.com, and are expected to be mailed on September 21, 2023 to shareholders of record as of the close of business on August 30, 2023

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy - - Combined portfolio creates the industry's largest, most advanced, well-protected deuterated DMT program - - Combination creates the largest intellectual property portfolio in the psychedelic drug development sector with 28 patents granted and 158 patents pending - - Creates strong synergies by combining key assets, personnel, capabilities and intellectual property, as well as access to world-leading scientific and clinical collaborators - -

Cybin Inc. (NEO:CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", today reported unaudited financial results for its first quarter ended June 30, 2022 and recent business highlights. "Looking back at the last 12 months, we have made positive progress toward our goal of advancing psychedelics to therapeutics. In that time, we have moved from the lab to the clinic where we now have two major development programs underway," said Doug Drysdale, Chief Executive Officer of Cybin. "Our lead candidate CYB003 is the first novel psilocybin analog to be evaluated in a Phase 1/2a trial for the treatment of major depressi